MARKET

SESN

SESN

Sesen Bio, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.400
+0.040
+2.94%
After Hours: 1.440 +0.04 +2.86% 19:56 09/30 EDT
OPEN
1.470
PREV CLOSE
1.360
HIGH
1.540
LOW
1.350
VOLUME
7.20M
TURNOVER
--
52 WEEK HIGH
1.540
52 WEEK LOW
0.3700
MARKET CAP
164.04M
P/E (TTM)
-4.3873
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
BB, CODX among premarket gainers
Sunworks (SUNW) +355%.Polar Power (POLA) +88%.The E.W. Scripps Company (SSP) +68% on ION Media acquisition.SPI Energy (SPI) +51%.LogicBio Therapeutics (LOGC) +45%.Owens & Minor (OMI) +28% after raising full-year guidance.Electrameccanica Vehicles (SOLO) +16% after announcing its EV enters
Seekingalpha · 6d ago
GME, CVNA among premarket gainers
AIM ImmunoTech (AIM) +25% on receiving significant positive survival results in pancreatic cancer from Erasmus University Medical Center.GameStop (GME) +18% after RC Ventures discloses stake.Rockwell Medical (RMTI) +13%.Cassava Sciences (SAVA) +13% on insider buying.Carvana (CVNA) +13% as
Seekingalpha · 09/22 12:24
We Think Sesen Bio (NASDAQ:SESN) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Simply Wall St. · 09/15 15:09
Sesen Bio to Provide Business Update at the H. C. Wainwright 22nd Annual Global Investment Conference
Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the H. C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020
Business Wire · 09/08 11:00
Sesen Bio (SESN) Looks Good: Stock Adds 6.2% in Session
Sesen Bio (SESN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Zacks · 09/01 12:41
Sesen Bio shares are trading lower after the company reported worse-than-expected Q2 EPS results. UPDATE: Shares have reversed since then.
Benzinga · 08/10 15:08
Sesen Bio Q2 EPS $(0.24) Misses $(0.09) Estimate
Sesen Bio (NASDAQ:SESN) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.09) by 166.67 percent. This is a 64.18 percent increase over losses of $(0.67) per share from the
Benzinga · 08/10 11:46
Sesen Bio Reports Second Quarter 2020 Financial Results and Business Update
Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the second quarter ended June 30, 2020. The Company also provided an update
Business Wire · 08/10 11:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SESN. Analyze the recent business situations of Sesen Bio, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SESN stock price target is 3.417 with a high estimate of 5.00 and a low estimate of 2.250.
EPS
Institutional Holdings
Institutions: 61
Institutional Holdings: 30.33M
% Owned: 25.88%
Shares Outstanding: 117.17M
TypeInstitutionsShares
Increased
14
2.36M
New
11
469.26K
Decreased
6
1.11M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.50%
Pharmaceuticals & Medical Research
+0.51%
Key Executives
President/Chief Executive Officer/Director
Thomas Cannell
Chief Financial Officer
Monica Forbes
Chief Technology Officer
Glen MacDonald
Chief Accounting Officer/Controller
Kirstin Anderson
Vice President/Director of Investor Relations
Erin Clark
Vice President - Business Development
Omar Rifi
General Counsel/Secretary
Mark Sullivan
Other
Dennis Kim
Independent Director
Carrie Bourdow
Independent Director
Jay Duker
Independent Director
Jane Henderson
Independent Director
Jason Keyes
Independent Director
Daniel Lynch
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SESN
Sesen Bio, Inc., formerly Eleven Biotherapeutics, Inc., is a late-stage clinical company that provides targeted protein therapeutics (TPT) platform. The Company is focused on developing antibody-drug conjugate (ADC) therapies for the treatment of cancer. Its product pipeline includes Vicinium, Vicinium in combination with checkpoint inhibator, durvalumab, and VB6-845d. The Company’s lead program, Vicinium, is a fusion protein in Phase III development for the treatment of non-muscle invasive bladder cancer (NMIBC). It targets epithelial cell adhesion molecule (EpCAM) antigens on the surface of tumor cells to deliver a potent cytotoxin, Pseudomonas Exotoxin A (ETA) directly to cancer cells.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Sesen Bio Inc stock information, including NASDAQ:SESN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SESN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SESN stock methods without spending real money on the virtual paper trading platform.